

## List of tables

<b>Table No.</b>	<b>Title</b>	<b>Page No.</b>
3.1	Regressed calibration curve of ETO in ACN at 284 nm	40
3.2	Regressed calibration curve of ETO in PBS pH 7.4 at 284 nm	41
3.3	Intraday precision and accuracy of ETO in ACN (n= 6)	42
3.4	Interday precision and accuracy for ETO in ACN (n= 6)	42
3.5	Intraday precision and accuracy of ETO in PBS pH 7.4 (n= 6)	43
3.6	Interday precision and accuracy for ETO in PBS pH 7.4 (n= 6)	43
3.7	Regressed calibration curve of ETO in cell lysate.	46
3.8	Intraday and interday precision and accuracy of ETO from cell lysis solution (n= 5)	47
3.9	Extraction recovery of ETO from cell lysate (mean $\pm$ S. D., n= 5)	47
3.10	Regressed calibration curve of CH <sub>3</sub> O-PEG-OH (M.W. 2000) at $\lambda$ 525 nm	49
3.11	Regressed calibration curve of CH <sub>3</sub> O-PEG-OH (M.W 5000) at $\lambda$ 525 nm	50
3.12	Regressed calibration curve of YIGSR-NH <sub>2</sub> at $\lambda$ 345 nm	51
3.13	Regressed calibration curve of EILDV-NH <sub>2</sub> at $\lambda$ 345 nm	52
4.1	Synthesis of PEG-PCL di-block copolymer of various molecular weight	57
4.2	Characteristics of synthesized PEG-b-PCL di-block copolymers	59
5.1	Effect of different organic solvent on particle size and percent drug entrapment of MPCL micelles	80
5.2	Effect of stirring speed on particle size and percent drug entrapment of MPCL micelles	81
5.3	Effect of rate of addition of organic solvent to aqueous phase on particle size and drug entrapment of MPCL micelles	82
5.4	Influence of ratio of drug to polymer on particle size and percent drug entrapment of MPCL220, MPCL235 and MPCL250 micelles	85
5.5	Influence of ratio of drug to polymer on particle size and percent drug entrapment of MPCL550, MPCL570 and MPCL5100 micelles	85

5.6	Influence of ratio of aqueous to organic phase on particle size and percent drug entrapment of MPCL220, MPCL235 and MPCL250 micelles	86
5.7	Influence of ratio of aqueous to organic phase on particle size and percent drug entrapment of MPCL550, MPCL570 and MPCL5100 micelles	86
5.8	Percent drug loading of ETO in MPCL220, MPCL235 and MPCL250 micelles with different amount of ETO	89
5.9	Percent drug loading of ETO in MPCL550, MPCL570 and MPCL5100 micelles with different amount of ETO	90
5.10	Average zeta potential of MPCL micellar formulation	93
5.11	Critical micelle concentration (CMC) of various MPCL micelles	95
5.12	Zeta potentials of MPCL micelles in ionic solution containing various concentration of NaCl	98
5.13	Fixed aqueous layer thickness (FALT) of ETO loaded and placebo MPCL micelles	98
5.14	Influence on particle size of MPCL220, MPCL235 and MPCL250 micelles incubated with PBS in absence and presence of BSA	102
5.15	Influence on particle size of MPCL550, MPCL570 and MPCL5100 micelles incubated with PBS in absence and presence of BSA	103
5.16	PEG surface density and average distance (nm) between two neighboring chain of MPCL micelles	106
5.17	Effect of ETO injection and ETO loaded micelles on the hemolytic effect after incubation with erythrocyte at different time interval	108
6.1	Effect of incubation condition on percent conjugation of peptide	122
6.2	Effect of time of incubation on percent conjugation of peptide	123
6.3	Effect of ratio of functional polymer to peptide on percent conjugation of peptide	123
6.4	Effect of peptide conjugation on particle size, zeta potential and percent drug entrapment	124
6.5	Redispersibility index of micellar formulations at various weight ratios of total solid content to sucrose	129

6.6	Redispersibility index of micellar formulations at various weight ratios of total solid content to trehalose	130
6.7	Redispersibility index of micellar formulations using various ratio of total solid content to sucrose and poloxamer-188	132
6.8	<i>In vitro</i> release study profile of MPCL235, YPCL235 and EPCL235 micelles in PBS pH 7.4	134
6.9	<i>In vitro</i> release study profile of MPCL570, YPCL570 and EPCL570 micelles in PBS pH 7.4	134
6.10	Influence on particle size of MPCL235, YPCL235 and EPCL235 micelles at different storage conditions	137
6.11	Influence on percent drug loading of MPCL235, YPCL235 and EPCL235 micelles at different storage conditions	137
6.12	Influence on particle size of MPCL570, YPCL570 and EPCL570 micelles at different storage conditions	138
6.13	Influence on percent drug loading of MPCL570, YPCL570 and EPCL570 micelles at different storage conditions	138
7.1	Percent viability of B16F10 cells treated with various concentrations of ETO at different incubation time period	149
7.2	Percent viability of B16F10 cells treated with various concentrations of MPCL235 at different incubation time period	149
7.3	Percent viability of B16F10 cells treated with various concentrations of YPCL235 at different incubation time period	150
7.4	Percent viability of B16F10 cells treated with various concentrations of EPCL235 at different incubation time period	152
7.5	Percent viability of B16F10 cells treated with various concentrations of MPCL 570 at different incubation time period	153
7.6	Percent viability of B16F10 cells treated with various concentrations of YPCL 570 at different incubation time period	154
7.7	Percent viability of B16F10 cells treated with various concentrations of EPCL 570 at different incubation time period	154
7.8	Inhibitory concentration (50%) of various formulations at different time incubation with B16F10 cells	155

7.9	Percent viability of B16F10 cells treated with various concentrations of MPCL235-P and MPCL570-P at different incubation time period	158
7.10	Subtoxic dose (Half and quarter IC <sub>50</sub> value, 48 h incubation) of ETO and micellar formulations and their respective code used for invitro cell line studies	160
7.11	Percent colony inhibition of B16F10 cells after treatment with subtoxic dose of plain ETO and micellar formulations	169
7.12	Percent cell migration of B16F10 cells after treatment with plain ETO, non conjugated micelles and peptide conjugated micelles	171
7.13	Percent cell adhesion of B16F10 cells after treatment with micellar formulation against YIGSR-NH <sub>2</sub> and EILDV-NH <sub>2</sub> coated plate	176
7.14	Percent cellular uptake of drug by B16F10 cells after incubation of ETO and ETO loaded micelles for two h	181
7.15	Effect of ETO and micellar formulation induced cell cycle perturbation and apoptosis in B16F10 cells	184
8.1	Influence of the amount of stannous chloride on the labeling efficiency of free ETO	197
8.2	Influence of amount of stannous chloride on the labeling efficiency of MPCL235, YPCL235 and EPCL235 micelles	198
8.3	Influence of amount of stannous chloride on the labeling efficiency of MPCL570, YPCL570 and EPCL570 micelles	198
8.4	Stability of <sup>99m</sup> Tc labeled ETO, MPCL235, YPCL235 and EPCL235 micelles in normal saline	199
8.5	Stability of <sup>99m</sup> Tc labeled etoposide, MPCL570, YPCL570 and EPCL570 micelles in normal saline	199
8.6	Biodistribution of <sup>99m</sup> Tc-labeled ETO after intravenous injection in EAT bearing Balb/c mice	200
8.7	Biodistribution of <sup>99m</sup> Tc-labeled MPCL235 after intravenous injection in EAT bearing Balb/c mice	201
8.8	Biodistribution of <sup>99m</sup> Tc-labeled YPCL235 after intravenous injection in EAT bearing Balb/c mice	201

8.9	Biodistribution of $^{99m}\text{Tc}$ -labeled EPCL235 after intravenous injection in EAT bearing Balb/c mice	202
8.10	Biodistribution of $^{99m}\text{Tc}$ -labeled MPCL570 after intravenous injection in EAT bearing Balb/c mice	202
8.11	Biodistribution of $^{99m}\text{Tc}$ -labeled YPCL570 after intravenous injection in EAT bearing Balb/c mice	203
8.12	Biodistribution of $^{99m}\text{Tc}$ -labeled EPCL570 after intravenous injection in EAT bearing Balb/c mice	203
8.13	Effect of <i>in vitro</i> ETO and ETO loaded micelles treated B16F10 cells on inhibition of nodule formation in C57BL/6 mice	212
8.14	Effect of intravenous treatment of ETO and ETO loaded micellar formulations on inhibition of pulmonary metastatic nodule formation of B16F10 cells inoculated C57BL/6 mice	215